Asgar Ali
Research Subjects
Asgar Ali has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Sadhana Sharma
Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India
5 shared publications - Krishnan Hajela
School of Life Sciences, Devi Ahilya University, Indore, India
4 shared publications - Sundeep Singh Saluja
Central Molecular Lab, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
3 shared publications Apurva
2 shared publicationsArun Kumar
Central Molecular Laboratory, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
2 shared publications- Bandana Kumari
Department of Biochemistry, All India Institute of Medical Sciences, Patna, India
2 shared publications
Latest Publications
- 1 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , e802-e811
High Seropositivity to rK39 and Capture of Leishmania -Infected Sand Flies in Bihar and Jharkhand Emphasize the Need for Post-Elimination Surveillance of Visceral Leishmaniasis in India
Background: India is transitioning to the visceral leishmaniasis (VL) post-elimination phase where robust surveillance is critical to sustaining elimination. We conducted a targeted longitudinal study combining epidemiological, serological, and entomological data in endemic villages in Bihar and Jharkhand states to assess active VL transmission levels. Methods: Our investigation was conducted in the villages of Rahar Diyara, Bihar, and Murbhanga, Jharkhand, based on spatial distribution of recently reported VL cases. Samples were collected quarterly from December 2021 to September 2022 in Rahar Diyara, and April 2022 to May 2023 in Murbhanga, to determine seroprevalence against Leishmania rK39 antigen. Sand flies were collected bi-weekly in Rahar Diyara (February to December, 2022) and Murbhanga (April to December, 2022) from different microhabitats and analyzed by qPCR targeting Leishmania kDNA. Results: rK39 Leishmania seroprevalence ranged from 20% to 30% in both villages. Murbhanga, an outbreak village, exhibited higher antibody levels in 9–23% of subjects compared with the low incidence village, Rahar Diyara (3–6%), reflecting a higher intensity of transmission in Murbhanga. Despite implementation of indoor residual spraying, Leishmania-infected sand flies were found in both villages, with 1.4% (4/285) and 1.2% (5/431) positive pools in Rahar Diyara and Murbhanga, respectively. Infected sand fly pools were collected from diverse microhabitats, predominantly from vegetation in Rahar Diyara and cattle enclosures in Murbhanga, indicative of focal and distinct patterns of transmission. Conclusions: Low-level Leishmania transmission persists in India highlighting criticality of continued surveillance. Combining epidemiological, serological, and entomological surveys improves rapid outbreak assessment and intervention, and enhances efficacy of surveillance to sustain VL elimination.
- 1 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , e802-e811
High Seropositivity to rK39 and Capture of Leishmania -Infected Sand Flies in Bihar and Jharkhand Emphasize the Need for Post-Elimination Surveillance of Visceral Leishmaniasis in India
Background: India is transitioning to the visceral leishmaniasis (VL) post-elimination phase where robust surveillance is critical to sustaining elimination. We conducted a targeted longitudinal study combining epidemiological, serological, and entomological data in endemic villages in Bihar and Jharkhand states to assess active VL transmission levels. Methods: Our investigation was conducted in the villages of Rahar Diyara, Bihar, and Murbhanga, Jharkhand, based on spatial distribution of recently reported VL cases. Samples were collected quarterly from December 2021 to September 2022 in Rahar Diyara, and April 2022 to May 2023 in Murbhanga, to determine seroprevalence against Leishmania rK39 antigen. Sand flies were collected bi-weekly in Rahar Diyara (February to December, 2022) and Murbhanga (April to December, 2022) from different microhabitats and analyzed by qPCR targeting Leishmania kDNA. Results: rK39 Leishmania seroprevalence ranged from 20% to 30% in both villages. Murbhanga, an outbreak village, exhibited higher antibody levels in 9–23% of subjects compared with the low incidence village, Rahar Diyara (3–6%), reflecting a higher intensity of transmission in Murbhanga. Despite implementation of indoor residual spraying, Leishmania-infected sand flies were found in both villages, with 1.4% (4/285) and 1.2% (5/431) positive pools in Rahar Diyara and Murbhanga, respectively. Infected sand fly pools were collected from diverse microhabitats, predominantly from vegetation in Rahar Diyara and cattle enclosures in Murbhanga, indicative of focal and distinct patterns of transmission. Conclusions: Low-level Leishmania transmission persists in India highlighting criticality of continued surveillance. Combining epidemiological, serological, and entomological surveys improves rapid outbreak assessment and intervention, and enhances efficacy of surveillance to sustain VL elimination.
- Open Access
Lipoxins as Modulators of Diseases
Lipoxins were discovered 40 years ago, and since then, their beneficial roles for human health have been confirmed in numerous studies. These small molecules belong to the eicosanoid class of compounds, which are generated metabolically by lipoxygenases. Lipoxins are released during various diseases and conditions, including but not limited to systemic inflammation, infection, asthma, cancer, diabetes, and cardiovascular disorders. Recently, several synthetic lipoxin analogs have been developed that also exhibit potent anti-inflammatory properties. In this review, we discuss the inflammation-resolving roles of lipoxins in various major diseases. Further, we summarize the latest reports on the use of synthetic lipoxins as potential therapeutic agents and discuss the role of aspirin-dependent lipoxin production in alleviating various diseases, including cancer.
Open AccessLipoxins as Modulators of Diseases
Lipoxins were discovered 40 years ago, and since then, their beneficial roles for human health have been confirmed in numerous studies. These small molecules belong to the eicosanoid class of compounds, which are generated metabolically by lipoxygenases. Lipoxins are released during various diseases and conditions, including but not limited to systemic inflammation, infection, asthma, cancer, diabetes, and cardiovascular disorders. Recently, several synthetic lipoxin analogs have been developed that also exhibit potent anti-inflammatory properties. In this review, we discuss the inflammation-resolving roles of lipoxins in various major diseases. Further, we summarize the latest reports on the use of synthetic lipoxins as potential therapeutic agents and discuss the role of aspirin-dependent lipoxin production in alleviating various diseases, including cancer.
- 20 June 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 38 (1) , 102-109
Evaluation of C4b as an adjunct marker in symptomatic RT-PCR negative Covid-19 cases
Introduction Detecting low viral load has been a challenge in this pandemic, which has led to its escalated transmission. Complement activation has been implicated in pathogenesis of Covid-19 infection. Thus, evaluation of complement activation in suspected Covid-19 infection may help to detect infection and limit false negative cases thus limiting transmission of infection. We speculate that measuring C4b, produced from an activated complement system due to the presence of Covid-19 may help in its detection, even when the viral titers are low. Methods Plasma C4b levels of symptomatic RT-PCR positive patients (cases, n = 40); symptomatic RT-PCR negative patients (n = 35) and asymptomatic RT-PCR negative controls (n = 40) were evaluated. Plasma C5b-9, IL-6, D-dimer and C1-Inhibitor (C1-INH) were also measured in cases and controls. ELISA kits were used for all measurements. Statistical analyses were carried out using Stata, version 12 (Stata Corp., Texas, USA). Results C4b levels were found to be significantly increased in RT-PCR positive patients as compared to asymptomatic RT-PCR negative controls. RT-PCR negative but symptomatic patients still showed increased C4b levels. The significantly higher levels of C4b in cases with a cut-off value of ≥ 116 ng/ml with optimum sensitivity and specificity of 80% and 52% respectively is indicative of its possible use as an adjunct marker. Increased levels of D-dimer, IL6, along with decreased levels of C1-INH were found in cases compared to controls. Whereas, C5b-9 levels were not significantly raised in cases. Conclusions The results of our study suggests that plasma C4b may help to detect infection in false negative cases of RT-PCR that escape detection owing to low viral load. However, to confirm it a large-scale study is needed.
- 20 June 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 38 (1) , 102-109
Evaluation of C4b as an adjunct marker in symptomatic RT-PCR negative Covid-19 cases
Introduction Detecting low viral load has been a challenge in this pandemic, which has led to its escalated transmission. Complement activation has been implicated in pathogenesis of Covid-19 infection. Thus, evaluation of complement activation in suspected Covid-19 infection may help to detect infection and limit false negative cases thus limiting transmission of infection. We speculate that measuring C4b, produced from an activated complement system due to the presence of Covid-19 may help in its detection, even when the viral titers are low. Methods Plasma C4b levels of symptomatic RT-PCR positive patients (cases, n = 40); symptomatic RT-PCR negative patients (n = 35) and asymptomatic RT-PCR negative controls (n = 40) were evaluated. Plasma C5b-9, IL-6, D-dimer and C1-Inhibitor (C1-INH) were also measured in cases and controls. ELISA kits were used for all measurements. Statistical analyses were carried out using Stata, version 12 (Stata Corp., Texas, USA). Results C4b levels were found to be significantly increased in RT-PCR positive patients as compared to asymptomatic RT-PCR negative controls. RT-PCR negative but symptomatic patients still showed increased C4b levels. The significantly higher levels of C4b in cases with a cut-off value of ≥ 116 ng/ml with optimum sensitivity and specificity of 80% and 52% respectively is indicative of its possible use as an adjunct marker. Increased levels of D-dimer, IL6, along with decreased levels of C1-INH were found in cases compared to controls. Whereas, C5b-9 levels were not significantly raised in cases. Conclusions The results of our study suggests that plasma C4b may help to detect infection in false negative cases of RT-PCR that escape detection owing to low viral load. However, to confirm it a large-scale study is needed.
- 23 December 2021
- Published by Springer Nature in Current Molecular Biology Reports
- Vol. 7 (4) , 41-66
Cell Death: a Molecular Perspective
- 23 December 2021
- Published by Springer Nature in Current Molecular Biology Reports
- Vol. 7 (4) , 41-66
Cell Death: a Molecular Perspective
- Open Access
- 9 August 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (8) , e0009101
Impact of IRS: Four-years of entomological surveillance of the Indian Visceral Leishmaniases elimination programme
Background: In 2005, Bangladesh, India and Nepal agreed to eliminate visceral leishmaniasis (VL) as a public health problem. The approach to this was through improved case detection and treatment, and controlling transmission by the sand fly vector Phlebotomus argentipes, with indoor residual spraying (IRS) of insecticide. Initially, India applied DDT with stirrup pumps for IRS, however, this did not reduce transmission. After 2015 onwards, the pyrethroid alpha-cypermethrin was applied with compression pumps, and entomological surveillance was initiated in 2016. Methods: Eight sentinel sites were established in the Indian states of Bihar, Jharkhand and West Bengal. IRS coverage was monitored by household survey, quality of insecticide application was measured by HPLC, presence and abundance of the VL vector was monitored by CDC light traps, insecticide resistance was measured with WHO diagnostic assays and case incidence was determined from the VL case register KAMIS. Results: Complete treatment of houses with IRS increased across all sites from 57% in 2016 to 70% of houses in 2019, rising to >80% if partial house IRS coverage is included (except West Bengal). The quality of insecticide application has improved compared to previous studies, average doses of insecticide on filters papers ranged from 1.52 times the target dose of 25mg/m2 alpha-cypermethrin in 2019 to 1.67 times in 2018. Resistance to DDT has continued to increase, but the vector was not resistant to carbamates, organophosphates or pyrethroids. The annual and seasonal abundance of P. argentipes declined between 2016 to 2019 with an overall infection rate of 0.03%. This was associated with a decline in VL incidence for the blocks represented by the sentinel sites from 1.16 per 10,000 population in 2016 to 0.51 per 10,000 in 2019. Conclusion: Through effective case detection and management reducing the infection reservoirs for P. argentipes in the human population combined with IRS keeping P. argentipes abundance and infectivity low has reduced VL transmission. This combination of effective case management and vector control has now brought India within reach of the VL elimination targets.
- 9 August 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (8) , e0009101
Open AccessImpact of IRS: Four-years of entomological surveillance of the Indian Visceral Leishmaniases elimination programme
Background: In 2005, Bangladesh, India and Nepal agreed to eliminate visceral leishmaniasis (VL) as a public health problem. The approach to this was through improved case detection and treatment, and controlling transmission by the sand fly vector Phlebotomus argentipes, with indoor residual spraying (IRS) of insecticide. Initially, India applied DDT with stirrup pumps for IRS, however, this did not reduce transmission. After 2015 onwards, the pyrethroid alpha-cypermethrin was applied with compression pumps, and entomological surveillance was initiated in 2016. Methods: Eight sentinel sites were established in the Indian states of Bihar, Jharkhand and West Bengal. IRS coverage was monitored by household survey, quality of insecticide application was measured by HPLC, presence and abundance of the VL vector was monitored by CDC light traps, insecticide resistance was measured with WHO diagnostic assays and case incidence was determined from the VL case register KAMIS. Results: Complete treatment of houses with IRS increased across all sites from 57% in 2016 to 70% of houses in 2019, rising to >80% if partial house IRS coverage is included (except West Bengal). The quality of insecticide application has improved compared to previous studies, average doses of insecticide on filters papers ranged from 1.52 times the target dose of 25mg/m2 alpha-cypermethrin in 2019 to 1.67 times in 2018. Resistance to DDT has continued to increase, but the vector was not resistant to carbamates, organophosphates or pyrethroids. The annual and seasonal abundance of P. argentipes declined between 2016 to 2019 with an overall infection rate of 0.03%. This was associated with a decline in VL incidence for the blocks represented by the sentinel sites from 1.16 per 10,000 population in 2016 to 0.51 per 10,000 in 2019. Conclusion: Through effective case detection and management reducing the infection reservoirs for P. argentipes in the human population combined with IRS keeping P. argentipes abundance and infectivity low has reduced VL transmission. This combination of effective case management and vector control has now brought India within reach of the VL elimination targets.
- Open Access
- 21 July 2021
- Published by IntechOpen
Advances in Adoptive Cellular Therapy (ACT)
Adoptive T cell therapy (ACT) is getting acknowledged as the Advanced Therapy Medicinal Products (ATMPs) in many countries and it has evolved as one of the newest regimens to treat cancer. Developed gradually by the basic understanding of cells, involved in innate and adaptive immunity, ACT has emerged as one of the successful immunotherapies in recent times. It broadly includes various cell types such as stem cells, T cells, dendritic cells and Natural Killer cells. By the applications of genetic engineering and advanced cell culture techniques, these cells from patients’ blood, can be manipulated to train them for better efficacy against specific tumor cells. However, only some cells’ subsets have shown promising regression for certain cancer cells types. To understand the reason behind this, technical knowledge about the tumor antigens presentation, tumor microenvironment (TME), hosts’ immune responses and possible issues in the manufacturing of adoptive cellular material for infusion in patients are being explored further. This chapter brings together development of immune cells from basic research to clinical use, newer approaches which have been taken to address the resistance of ACT and future promises of this therapy.
- 21 July 2021
- Published by IntechOpen
Open AccessAdvances in Adoptive Cellular Therapy (ACT)
Adoptive T cell therapy (ACT) is getting acknowledged as the Advanced Therapy Medicinal Products (ATMPs) in many countries and it has evolved as one of the newest regimens to treat cancer. Developed gradually by the basic understanding of cells, involved in innate and adaptive immunity, ACT has emerged as one of the successful immunotherapies in recent times. It broadly includes various cell types such as stem cells, T cells, dendritic cells and Natural Killer cells. By the applications of genetic engineering and advanced cell culture techniques, these cells from patients’ blood, can be manipulated to train them for better efficacy against specific tumor cells. However, only some cells’ subsets have shown promising regression for certain cancer cells types. To understand the reason behind this, technical knowledge about the tumor antigens presentation, tumor microenvironment (TME), hosts’ immune responses and possible issues in the manufacturing of adoptive cellular material for infusion in patients are being explored further. This chapter brings together development of immune cells from basic research to clinical use, newer approaches which have been taken to address the resistance of ACT and future promises of this therapy.
- 1 June 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 162, 103348
Cross-talk between next generation sequencing methodologies to identify genomic signatures of esophageal cancer
- 1 June 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 162, 103348
Cross-talk between next generation sequencing methodologies to identify genomic signatures of esophageal cancer
- 1 May 2021
- Published by Elsevier in Pharmacological Research
- Vol. 167, 105544
Ligand decorated biodegradable nanomedicine in the treatment of cancer
- 1 May 2021
- Published by Elsevier in Pharmacological Research
- Vol. 167, 105544
Ligand decorated biodegradable nanomedicine in the treatment of cancer
- 21 April 2016
- Published by Taylor & Francis in Biomarkers
- Vol. 21 (8) , 716-720
Allelic loss atPTENlocus leads to progression of colorectal carcinoma among North Indian patients
We evaluated the loss of heterozygosity (LOH) at 10q23.3 locus of microsatellite markers; D10S198, D10S192, and D10S541 of PTEN gene in 223 North Indian colorectal cancer (CRC) specimens. DNA was isolated and microsatellite-specific markers polymerase chain reaction was performed. Out of total 223 cases 102 showed LOH for at least one of the locus. In addition, thereto a significant association was found with the clinicopathologic features like grade of differentiation, clinical stage, invasion, lymph node invasion, and the clinical outcome (p < 0.05). These data argue that the given markers to check the possible LOH of PTEN gene at locus 10q23.3 could be considered as one of the diagnostic markers in CRC.
- 21 April 2016
- Published by Taylor & Francis in Biomarkers
- Vol. 21 (8) , 716-720
Allelic loss atPTENlocus leads to progression of colorectal carcinoma among North Indian patients
We evaluated the loss of heterozygosity (LOH) at 10q23.3 locus of microsatellite markers; D10S198, D10S192, and D10S541 of PTEN gene in 223 North Indian colorectal cancer (CRC) specimens. DNA was isolated and microsatellite-specific markers polymerase chain reaction was performed. Out of total 223 cases 102 showed LOH for at least one of the locus. In addition, thereto a significant association was found with the clinicopathologic features like grade of differentiation, clinical stage, invasion, lymph node invasion, and the clinical outcome (p < 0.05). These data argue that the given markers to check the possible LOH of PTEN gene at locus 10q23.3 could be considered as one of the diagnostic markers in CRC.